MedTrace Logo

A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users

NCT02094599 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2014-05-13

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the abuse potential of dronabinol oral solution in recreational cannabinoid users.

Conditions

  • Drug Abuse, Medication

Interventions

DRUG

Dronabinol 10 mg

Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.

DRUG

Dronabinol 30 mg

Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.

DRUG

Placebo

Matching placebo provided in capsules or as an oral solution in syringes.

Sponsors & Collaborators

  • INSYS Therapeutics Inc

    lead INDUSTRY

Principal Investigators

  • Larry Dillaha, MD · INSYS Therapeutics Inc

  • Michael McDonnell, MD · INC Research Toronto, Inc.

Study Design

Allocation
NA
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02094599 on ClinicalTrials.gov